VivoSeq
Other

Statin

0

Pipeline Programs

19

Active Trials

36

Companies Involved

Statin is an early-stage landscape with 0 programs across 36 companies. The most active players are AstraZeneca, Boehringer Ingelheim, Pfizer.

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

5/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

227

clinical trials

Completed171 · 75%
Unknown status23 · 10%
Recruiting11 · 5%
Terminated10 · 4%
Not yet recruiting4 · 2%
Active, not recruiting4 · 2%
Other4 · 2%

Trial Activity

227 trials

KF2023#1-Trial: Influence of Statin Intake on Cellular Readouts
Recruiting··Phase 1·NCT06469450·15 enrolled
Statin Therapy in Patients With Early Stage ADPKD
Active, not recruiting·UUniversity of Colorado, Denver·Phase 4·NCT03273413·150 enrolled
Safety of Bryostatin in Patients With MS
Active, not recruiting··Phase 1·NCT06190912·20 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)